Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 10.54 SEK -4.01%
Market Cap: 3B SEK

Vicore Pharma Holding AB
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Vicore Pharma Holding AB
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Vicore Pharma Holding AB
STO:VICO
Cash from Operating Activities
-kr344.1m
CAGR 3-Years
-8%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cash from Operating Activities
kr325.2m
CAGR 3-Years
5%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash from Operating Activities
kr240.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cash from Operating Activities
kr742m
CAGR 3-Years
16%
CAGR 5-Years
20%
CAGR 10-Years
18%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash from Operating Activities
kr7.4B
CAGR 3-Years
15%
CAGR 5-Years
7%
CAGR 10-Years
31%
BioArctic AB
STO:BIOA B
Cash from Operating Activities
-kr316.3m
CAGR 3-Years
-31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vicore Pharma Holding AB
Glance View

Market Cap
3B SEK
Industry
Biotechnology

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

VICO Intrinsic Value
3.4 SEK
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Vicore Pharma Holding AB's Cash from Operating Activities?
Cash from Operating Activities
-344.1m SEK

Based on the financial report for Sep 30, 2025, Vicore Pharma Holding AB's Cash from Operating Activities amounts to -344.1m SEK.

What is Vicore Pharma Holding AB's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-27%

Over the last year, the Cash from Operating Activities growth was -90%. The average annual Cash from Operating Activities growth rates for Vicore Pharma Holding AB have been -8% over the past three years , -27% over the past five years .

Back to Top